Format

Send to

Choose Destination
Immunol Lett. 1999 Mar;66(1-3):159-64.

The implications of antigenic diversity for vaccine development.

Author information

1
Research Center for AIDS and HIV Infection, New York Veterans Affairs Medical Center, NY 10010, USA. zollas01@mcrcr6.med.nyu.edu

Abstract

The reactivity of human monoclonal and polyclonal anti-HIV-1 antibodies demonstrates that shared epitopes, including those that induce neutralizing antibodies, exist and are recognized by the human immune system. A priori, there is no reason why cross-clade neutralizing antibodies could not be induced by an appropriately constructed HIV vaccine. But to construct such a vaccine, it is critical to understand, as completely as possible, the antigenic structure of HIV, to establish and identify immunologic classifications for HIV, and to choose rationally the minimum number and types of viruses from these immunologic groupings that will induce the broadest protective responses.

PMID:
10203049
DOI:
10.1016/s0165-2478(98)00176-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center